Incorporating Differential Gene Expression Analysis with Predictive Biomarkers to Identify Novel Therapeutic Drugs for Fuchs Endothelial Corneal Dystrophy
CONCLUSIONS: Based on differential gene expression signatures, several candidate drugs have been identified to reverse the disease phenotypes in FECD. Gene expression signature with LINCS small molecule prediction software can discover novel preclinical drug candidates for FECD.PMID:34258047 | PMC:PMC8260298 | DOI:10.1155/2021/5580595
Source: Journal of Ophthalmology - Category: Opthalmology Authors: Huaming Wen Ryan A Gallo Xiaosheng Huang Jiamin Cai Shaoyi Mei Ammad Ahmad Farooqi Jun Zhao Wensi Tao Source Type: research
More News: Allergy & Immunology | Databases & Libraries | Genetics | Opthalmology | Reflex Sympathetic Dystrophy